Participants with obesity had, after 1 year, more effective body weight loss maintenance with a combination of liraglutide and exercise program compared to either single treatment alone.
This meta-analysis of five RCTs (REDUCE-IT, ASCEND, R&P, STRENGTH and OMEMI) showed that Omega-3 fatty acids supplementation is associated with an increased risk of incident AF, compared to placebo.
ERA-EDTA 2021 Prof. Wanner presents the results of a post hoc analysis of EMPA-REG OUTCOME, in which potential mediators of the treatment effect of empagliflozin on kidney outcomes were explored.
This combined cohort study suggested that IL-6 and hs-CRP levels were associated with HF hospitalization and adverse outcomes in patients with AF. The risk for HF hospitalization increased with increasing inflammation scores of both inflammation markers.
Treatment with IV ferric carboxymaltose in patients with iron deficiency who had stabilized after acute HF led to greater improvements in health-related quality of life from week 4 to week 24 after discharge, compared to placebo.
The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.
Additional analyses of all events through the end of the intervention period and post-trial observational follow-up data showed reduction of MACE and all-cause death with SBP target <120 mmHg compared to SBP target <140 mmHg. With poll.
Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.
The Heart Failure Association of the European Society of Cardiology has published a consensus document with patient profiles that may be relevant for treatment implementation in HFrEF patients.
Following the results from the EMPEROR-Reduced trial, the CHMP has issued a recommendation for empagliflozin in patients with symptomatic chronic HFrEF with or without T2DM to reduce the combined risk of CV death or HF hospitalization.
The ERA-EDTA has launched the "Strong Kidneys" campaign to raise awareness about kidney disease and its prevention.
ERA-EDTA 2021 A post hoc analysis of the EMPA-REG OUTCOME trial suggests that hematocrit is the key driver of the renal benefit observed with empagliflozin.